INTRODUCTION
Serving as a central signaling hub that integrates multiple intra-and extracellular cues, the serine/threonine kinase mTOR is an attractive anticancer target. mTOR is involved in the formation of at least two multiprotein complexes, mTORC1 and mTORC2, that direct cell metabolism, growth, proliferation, survival, and angiogenesis.
Whereas signaling via the rapamycin-sensitive mTORC1 through its direct phosphorylation of the ribosomal protein S6 kinase 1 (S6K1) and the eukaryotic translation initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) is well understood and involved in the promotion of anabolic processes, including biosynthesis of proteins, lipids, and organelles, and limitation of catabolic processes such as autophagy ( 1 ), the biology of mTORC2 is far less clear. Although the authors of previous work showed that mTORC2, contrary to mTORC1, acts upstream of AKT and is necessary for the maximum activation of Akt via S 473 phosphorylation ( 2 ), the precise function and especially the regulation of mTORC2 has not yet been fully clarified.
Aberrant signaling of the epidermal growth factor receptor (EGFR) through amplification (40%) or overexpression (>60%) accounts for the most common mutational changes in primary glioblastoma, and EGFRvIII, a constitutively active genomic deletion variant of the EGFR, is the most frequent mutational variant found in glioblastoma, causing a persistent activation of the phosphoinositide 3-kinase (PI3K) signaling pathway ( 3 ).
By using this oncogenic EGFR variant, Tanaka et al. ( 4 ) show in this issue of Cancer Discovery that EGFRvIII stimulates mTORC2 activity, which promotes glioblastoma proliferation ( Fig. 1 ) . Most importantly, they propose an EGFRvIII/mTORC2/NF-κB signaling cascade and point out www.aacrjournals.org including NF-κB signaling, may underlie the resistance to rapamycin and the associated poor clinical outcome in some patients with glioblastoma. Dual inhibition of mTORC1 and mTORC2, which inhibits tumor growth and leads to tumor cell death in the presented preclinical paradigm, or mTORC2/chemotherapy combinations, may be worth investigating in the clinic. Another approach that aims for additive or even synergistic activity that is currently being attempted by the Brain Tumor Group of the European Organization for Research and Treatment of Cancer (EORTC 26082/22081) is the combination of mTOR inhibition not with chemo-but rather with radiotherapy (http://www.eortc.be). In this noncomparative actively controlled phase II study, CCI-779 at 25 mg or temozolomide is combined with radiotherapy in patients with newly diagnosed glioblastoma.
Studies to identify markers predicting response to EGFR inhibitors in patients with recurrent glioblastoma have shown significant correlation of response to therapy with coexpression of the PTEN tumor suppressor and the EGFR deletion mutant variant III (EGFRvIII) (10) . However, this has been suggested to be a prognostic phenomenon (11) . It may be worth testing these parameters with new therapies, such as mTORC2 inhibition plus chemotherapy, or other molecular parameters, like NDRG1 or NF-κB, for predictive properties in future trials.
The results presented here suggest mTORC2 as a target for combination cancer therapy and provide new insights into its role in mediating chemotherapy resistance, suggesting new treatment strategies. Preclinical data, including more glioblastoma-specific therapies, such as radiotherapy and temozolomide, will be important to delineate the next steps and possibly revitalize the EGFR/mTOR axis as a therapeutic target in glioblastoma.
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